301166.SHE Shanghai Universal Biotech Co.Ltd.
- Market cap
- CNY 2.51B
- P/E
- -
- P/B
- 1.29x
- ROE
- -0.5%
- Dividend yield
- 0.80%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 301166.SHE undervalued?
Graham numberThe Graham number of Shanghai Universal Biotech Co.Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanghai Universal Biotech Co.Ltd. fundamental analysis
No fundamental analysis for Shanghai Universal Biotech Co.Ltd. yet.
Shanghai Universal Biotech Co.Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanghai Universal Biotech Co.Ltd.
Shanghai Universal Biotech Co.,Ltd. distributes and supplies antibodies and protein products. The company offers antibodies, recombinant proteins, detection kits, antigens, and other products, as well as immunology reagents, molecular biology reagents, cell biology reagents and biochemical reagents, as well as reagent kits. It also provides technical services, technology promotion, technology information exchange, scientific and technology training, technology consulting, te…
Full company profileShanghai Universal Biotech Co.Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shanghai Universal Biotech Co.Ltd. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 787M | 849M | 1.11B | 1.20B | 1.23B | 1.12B | 1.08B | 1.22B |
| Gross Profit | 175M | 193M | 257M | 267M | 240M | 202M | 204M | 251M |
| Operating Income | 79.9M | 96.1M | 138M | 105M | 15.3M | -25.5M | -41.9M | -34.7M |
| EBITDA | 97.7M | 110M | 144M | 141M | 56.4M | 24.3M | -7.44M | -28.5M |
| Net Income | 57.9M | 76.5M | 109M | 107M | 40.3M | 10.1M | -22.9M | -10.2M |
| EPS | 0.89 | 1.18 | 1.25 | 1.23 | 0.47 | 0.12 | -0.26 | -0.12 |
| Balance Sheet | ||||||||
| Total Assets | 505M | 591M | 2.31B | 2.48B | 2.39B | 2.31B | 2.30B | 2.30B |
| Total Liabilities | 175M | 186M | 225M | 327M | 274M | 242M | 297M | 346M |
| Shareholders' Equity | 329M | 405M | 2.09B | 2.16B | 2.12B | 2.07B | 2.01B | 1.95B |
| Cash & Short-term Investments | 153M | 251M | 1.87B | 732M | 415M | 840M | 546M | 252M |
| Cash Flow | ||||||||
| Operating Cash Flow | 9.63M | 92.2M | 59.0M | -143M | -22.7M | 76.0M | 52.4M | - |
| Capital Expenditure | 5.47M | 4.95M | 14.3M | 61.5M | 63.2M | 71.2M | 96.1M | 35.6M |
| Free Cash Flow | 4.16M | 87.3M | 44.7M | -205M | -85.9M | 4.77M | -43.6M | -263M |
| Ratios | ||||||||
| ROE | 17.6% | 18.9% | 5.2% | 4.9% | 1.9% | 0.5% | -1.1% | -0.5% |
| ROA | 11.5% | 12.9% | 4.7% | 4.3% | 1.7% | 0.4% | -1.0% | -0.4% |
| Net Profit Margin | 7.4% | 9.0% | 9.8% | 8.9% | 3.3% | 0.9% | -2.1% | -0.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Shanghai Universal Biotech Co.Ltd. dividends
- Dividend yield
- 0.80%
- Forward dividend
- 0.60 CNY
- Payout ratio
- -
- Ex-dividend date
- Jun 1, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 20.0M | 0.23 | - |
| 2024 | CNY 40.7M | 0.47 | 401.2% |
| 2023 | CNY 78.8M | 0.91 | 195.5% |
| 2022 | CNY 44.3M | 0.51 | 41.5% |
| 2021 | CNY 20.2M | 0.23 | 18.6% |
| 2020 | CNY 382K | 0.01 | 0.5% |
| 2019 | CNY 20.7M | 0.32 | 35.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Shanghai Universal Biotech Co.Ltd.
- Insiders 55.05%
- Institutions 5.37%
- Public & others 39.58%
- Shares outstanding 86.2M
- Free float 40.5M
Shanghai Universal Biotech Co.Ltd. company profile
- Company name
- Shanghai Universal Biotech Co.Ltd.
- Ticker
- 301166.SHE
- ISIN
- CNE100005709
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 810
- Fiscal year end
- December
- Address
- Building 16, Shanghai, China, 201314
- Phone
- 86 40 0816 8068
- Website
- univ-bio.com
About Shanghai Universal Biotech Co.Ltd.
Shanghai Universal Biotech Co.,Ltd. distributes and supplies antibodies and protein products. The company offers antibodies, recombinant proteins, detection kits, antigens, and other products, as well as immunology reagents, molecular biology reagents, cell biology reagents and biochemical reagents, as well as reagent kits. It also provides technical services, technology promotion, technology information exchange, scientific and technology training, technology consulting, technology incubation and other services, as well as experimental services and software solutions. The company also sells products online. It serves colleges and universities, research institutes, hospitals, and biomedical companies. The company was founded in 2004 and is based in Shanghai, China.
Shanghai Universal Biotech Co.Ltd. management
10- Mr. Zhaowu LengChairman & GM · born 1970
- Ms. Min TangCFO, Deputy GM & Director · born 1980
- Ms. Xiaoping XuDeputy GM & Director · born 1970
- Mr. Yin ZhouDeputy GM & Director · born 1981
- Ms. Yanfang QiBoard Secretary & Deputy GM · born 1980
- Ms. Waying ChenDeputy General Manager · born 1984
- Ms. Bing HuDeputy General Manager · born 1983
- Ms. Wei LiaoDeputy General Manager · born 1984
- Ms. Hong Yang PanDeputy General Manager · born 1980
- Zhiwen LuAccounting Supervisor